Standard chemotherapy

Phase 3Small molecule

Roche

Standard chemotherapy is one of 201 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

200

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

PtosisActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Bladder CancerActive, not recruiting

Gastric Cancer Peritoneal MetastasesRecruiting

Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruiting

Metastatic Colorectal CancerRecruiting

Advanced Solid TumorsNot yet recruiting

Relapsed/refractoryRecruiting

Breast CancerPhase 3

Not yet recruiting

PtosisPreclinical

Active, not recruiting

Fallopian Tube CancerPreclinical

Active, not recruiting

Bladder CancerPreclinical

Active, not recruiting

Gastric Cancer Peritoneal MetastasesPhase 3

Recruiting

Advanced Solid Tumors With Neuroendocrine DifferentiationPhase 2

Not yet recruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Not yet recruiting

Relapsed/refractoryPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Standard chemotherapy

Roche

Phase 3

7 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Rilvegostomig

AstraZeneca

Preclinical

1 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 6

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 8

Lapatinib Plus Capecitabine

GSK

Preclinical

2 9

Trastuzuma

FFudan University

Preclinical

1 10

Atracurium Besylate

MMansoura University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Treatment

NCT06810791

Q2 2027

Phase 2Recruiting

Colorectal Cancer

NCT06856187

Phase 1/2Recruiting

Relapsed/refractory

NCT03319901

Q3 2027

Phase 2Not yet recruiting

Advanced Solid Tumors With Neuroendocrine Differentiation

NCT06531291

Q4 2027

Phase 3Not yet recruiting

Oligometastatic Disease

NCT06141070

Phase 1/2Not yet recruiting

Advanced Solid Tumors

NCT07260058

Clinical

Trials by Indication[1]

Breast Cancer7 trials

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00717405·52 enrolled

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 4·NCT04031885·4 enrolled

A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00559754·72 enrolled

Show 4 more trials

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer

Completed·PPeking Union Medical College Hospital·Phase 3·NCT02483767·98 enrolled

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Completed· Roche logo

Roche·Phase 3·NCT00281697·684 enrolled

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Recruiting·FFudan University·Phase 3·NCT07019363·1,903 enrolled

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Not yet recruiting·FFudan University·Phase 3·NCT05889871·916 enrolled

Pancreatic Cancer2 trials

Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

Unknown status·SSofia Perea, Director Clinical Trials Unit.·Phase 2·NCT01394120·60 enrolled

Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy

Unknown status·FFudan University·Phase 3·NCT03398291·300 enrolled

Small Cell Lung Cancer2 trials

Bevacizumab in Extensive Small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT00930891·143 enrolled

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Completed·—·Phase 2·NCT04263051·60 enrolled

Colorectal Cancer2 trials

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06856187·119 enrolled

Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)

Unknown status·FFudan University·Phase 3·NCT02965248·147 enrolled

Treatment2 trials

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Recruiting·NNanfang Hospital, Southern Medical University·Phase 3·NCT06810791·876 enrolled

LOTCOL Study: Local Treatment of Colo-rectal Liver Met

Terminated·OOslo University Hospital·N/A·NCT01867918·3 enrolled

29 more indications

Ovarian Cancer2 trials

Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines

Terminated·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 2·NCT03622931·21 enrolled

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Active, not recruiting·CCordgenics, LLC·Phase 3·NCT03949283·150 enrolled

Lung Cancer1 trial

A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Terminated· Roche logo

Roche·Phase 2·NCT00642824·3 enrolled

Ptosis1 trial

Use of the MiCK Assay for Apoptosis in AML

Completed·PPierian Biosciences··NCT00286845·50 enrolled

Non-Small Cell Lung Cancer1 trial

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT01951586·226 enrolled

Clear Cell Adenocarcinoma1 trial

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT03405454·46 enrolled

Growth1 trial

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Completed· Amgen logo

Amgen·Phase 3·NCT00911170·847 enrolled

Completed·—·Phase 3·NCT00718354·740 enrolled

Relapsed/Refractory1 trial

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Recruiting·—·Phase 1/2·NCT03319901·82 enrolled

Refractory Cancer1 trial

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

Completed·IInstitut Curie·Phase 2·NCT01771458·742 enrolled

Gastric Carcinoma1 trial

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04065139·66 enrolled

Chemotherapy1 trial

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Completed· Roche logo

Roche·Phase 2·NCT00643565·154 enrolled

Osteosarcoma1 trial

Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma

Unknown status·TTata Memorial Hospital·Phase 2/3·NCT00691236·60 enrolled

Acute Myeloid Leukemia1 trial

Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Completed·UUniversity of Ulm·Phase 3·NCT00893399·600 enrolled

Fallopian Tube Cancer1 trial

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00293293·43 enrolled

Post-surgical1 trial

TAilored Post-Surgical Therapy in Early Stage NSCLC

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT00775385·152 enrolled

Advanced Solid Tumors1 trial

Immune Cell Therapy for Advanced Solid Tumors

Not yet recruiting·LLiaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.·Phase 1/2·NCT07260058·48 enrolled

Advanced Solid Tumors With Neuroendocrine Differentiation1 trial

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Not yet recruiting·RRenJi Hospital·Phase 2·NCT06531291·80 enrolled

Lymphoma1 trial

A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT00269113·360 enrolled

Colonic Cancer1 trial

Proactive Management of Endoperitoneal Spread in Colonic Cancer

Unknown status·UUniversity of Roma La Sapienza·Phase 3·NCT02974556·140 enrolled

Colon Cancer1 trial

Adjuvant HIPEC in High Risk Colon Cancer

Completed·—·Phase 3·NCT02231086·204 enrolled

Metastatic Colorectal Cancer1 trial

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06841159·116 enrolled

Allogeneic Stem Cell Transplantation1 trial

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

Recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 3·NCT04184505·274 enrolled

Oligometastatic Disease1 trial

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Not yet recruiting·VVastra Gotaland Region·Phase 3·NCT06141070·240 enrolled

Randomized Controlled Trial1 trial

First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial

Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06922279·108 enrolled

Pleural Mesothelioma1 trial

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Completed·PPrECOG, LLC.·Phase 3·NCT04334759·214 enrolled

Malignant Solid Tumor1 trial

First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors

Terminated· Genmab logo

Genmab·Preclinical·NCT06391775·21 enrolled

Gastric Cancer Peritoneal Metastases1 trial

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric

Recruiting·MMagnus Nilsson·Phase 3·NCT07304271·262 enrolled

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for Standard chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Standard chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Breast Cancer7 trials

Pancreatic Cancer2 trials

Small Cell Lung Cancer2 trials

Colorectal Cancer2 trials

Treatment2 trials

Ovarian Cancer2 trials

Lung Cancer1 trial

Ptosis1 trial

Non-Small Cell Lung Cancer1 trial

Clear Cell Adenocarcinoma1 trial

Growth1 trial

Mesothelioma1 trial

Bladder Cancer1 trial

Esophageal Cancer1 trial

Relapsed/Refractory1 trial

Refractory Cancer1 trial

Gastric Carcinoma1 trial

Chemotherapy1 trial

Osteosarcoma1 trial

Acute Myeloid Leukemia1 trial

Fallopian Tube Cancer1 trial

Post-surgical1 trial

Advanced Solid Tumors1 trial

Advanced Solid Tumors With Neuroendocrine Differentiation1 trial

Lymphoma1 trial

Colonic Cancer1 trial

Colon Cancer1 trial

Metastatic Colorectal Cancer1 trial

Allogeneic Stem Cell Transplantation1 trial

Oligometastatic Disease1 trial

Randomized Controlled Trial1 trial

Pleural Mesothelioma1 trial

Malignant Solid Tumor1 trial

Gastric Cancer Peritoneal Metastases1 trial

References

Drug Info

Quick Facts

Related News